Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 1671 to 1680 of 2529

TitleReference numberPublishedLast updated
Pelvic floor dysfunction: prevention and non-surgical managementNG210
Pembrolizumab for adjuvant treatment of completely resected stage 3 melanomaTA766
Pembrolizumab for adjuvant treatment of renal cell carcinomaTA830
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancerTA1037
Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanomaTA837
Pembrolizumab for advanced melanoma not previously treated with ipilimumabTA366
Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancerTA851
Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiencyTA914
Pembrolizumab for treating advanced melanoma after disease progression with ipilimumabTA357
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapyTA692

Results per page

  1. 10
  2. 25
  3. 50
  4. All